Home  »  Business   »  In 2022, Myriad Genetics Inc. (NASDAQ: MYGN) Share...

In 2022, Myriad Genetics Inc. (NASDAQ: MYGN) Shares Will Likely Be Bullish

Myriad Genetics Inc. (NASDAQ:MYGN) shares, rose in value on Friday, 05/13/22, with the stock price up by 7.14% to the previous day’s close as strong demand from buyers drove the stock to $22.37.

Actively observing the price movement in the last trading, the stock closed the session at $20.88, falling within a range of $21.14 and $22.50. The value of beta (5-year monthly) was 1.58. Referring to stock’s 52-week performance, its high was $36.95, and the low was $18.98. On the whole, MYGN has fluctuated by -8.47% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.

Sponsored

With the market capitalization of Myriad Genetics Inc. currently standing at about $1.81 billion, investors are eagerly awaiting this quarter’s results, scheduled for May 02, 2022 – May 06, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.02, which is expected to increase to $0.05 for fiscal year $0.01 and then to about $0.16 by fiscal year 2022. Data indicates that the EPS growth is expected to be 101.50% in 2022, while the next year’s EPS growth is forecast to be 1,500.00%.

Analysts have estimated the company’s revenue for the quarter at $163.25 million, with a low estimate of $157.52 million and a high estimate of $168.92 million. According to the average forecast, sales growth in current quarter could jump up 5.60%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2022, the company’s y-o-y revenues would reach $692.66 million, representing an increase of 24.40% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that MYGN’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of MYGN currently trading nearly 3.89% and -4.97% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 52.34, while the 7-day volatility ratio is showing 8.74% which for the 30-day chart, stands at 5.69%. Furthermore, Myriad Genetics Inc. (MYGN)’s beta value is 1.57, and its average true range (ATR) is 1.25.

A comparison of Myriad Genetics Inc. (MYGN) with its peers suggests the former has fared considerably weaker in the market. MYGN showed an intraday change of 7.14% in last session, and over the past year, it shrunk by -18.30%%. On the other hand, the price of Abbott Laboratories (ABT) has risen 1.77% on the day. The stock, however, is off -7.13% from where it was a year ago. Additionally, there is a gain of 1.77% for BioMarin Pharmaceutical Inc. (BMRN) in last trading while the stock has seen an overall depriciation of 1.04%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 2.39%. Meanwhile, the Dow Jones Industrial Improved by 1.47%.

Data on historical trading for Myriad Genetics Inc. (NASDAQ:MYGN) indicates that the trading volumes over the past 3 months, they’ve averaged 550.95K. According to company’s latest data on outstanding shares, there are 80.83 million shares outstanding.

The stock has fallen by -18.95% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the MYGN stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam